CRSP
CRISPR Therapeutics AG
Price Chart
Latest Quote
$54.09
+1.00 (+1.88%)
Current Price
| Previous Close | $53.09 |
| Open | $54.41 |
| Day High | $55.79 |
| Day Low | $53.02 |
| Volume | 1,939,594 |
Stock Information
| Shares Outstanding | 98.48M |
| Total Debt | $787.64M |
| Cash Equivalents | $2.44B |
| Revenue | $4.10M |
| Net Income | $-568.53M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.33B |
| EPS (TTM) | $-6.17 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.56B |
| Sales | $4.10M |
| Income | $-568.53M |
| Book/sh | $18.83 |
| Cash/sh | $24.79 |
Financial Ratios
| Quick Ratio | 17.92 |
| Current Ratio | 17.96 |
| Debt/Eq | 43.41 |
Returns & Margins
| ROA | -14.06% |
| ROE | -31.21% |
| Operating Margin | -8933.33% |
Ownership
| Insider Ownership | 5.91% |
| Institutional Ownership | 80.91% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -14.12 |
| P/S | 1298.32 |
| P/B | 2.87 |
Analyst Data
| Recommendation | buy |
| Target Price | $83.52 |
Technical Indicators
| SMA20 | $52.47 |
| SMA50 | $52.75 |
| SMA200 | $55.53 |
| RSI | 45.51 |
| ATR | 3.0725 |
| Shares Float | 96.03M |
| Short Float | 25.74% |
| Short Ratio | 12.75 |
| Volatility | 1.70 |
| Rel Volume | 1.14 |
Performance History
| Week | +7.68% |
| Month | +13.66% |
| Quarter | +15.21% |
| 6 Months | -3.36% |
| YTD | +0.60% |
| Year | +25.24% |
| 3 Years | -11.02% |
| 5 Years | -57.41% |
| 10 Years | +283.89% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $54.09 | 1,941,400 |
| 2026-06-17 | $53.09 | 2,097,500 |
| 2026-06-16 | $52.02 | 1,103,400 |
| 2026-06-15 | $52.61 | 1,828,500 |
| 2026-06-12 | $49.80 | 1,149,200 |
| 2026-06-11 | $50.23 | 1,515,000 |
| 2026-06-10 | $49.44 | 1,409,200 |
| 2026-06-09 | $51.48 | 1,461,800 |
| 2026-06-08 | $51.60 | 1,131,300 |
| 2026-06-05 | $51.84 | 2,298,200 |
| 2026-06-04 | $56.95 | 3,301,000 |
| 2026-06-03 | $52.08 | 1,271,700 |
| 2026-06-02 | $52.02 | 1,372,800 |
| 2026-06-01 | $54.19 | 1,426,100 |
| 2026-05-29 | $56.18 | 1,931,800 |
| 2026-05-28 | $56.38 | 2,662,700 |
| 2026-05-27 | $53.53 | 1,839,500 |
| 2026-05-26 | $51.59 | 1,451,800 |
| 2026-05-22 | $50.36 | 1,548,300 |
| 2026-05-21 | $49.90 | 1,447,200 |
| 2026-05-20 | $48.55 | 1,725,000 |
| 2026-05-19 | $47.59 | 1,689,100 |
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
đ° Latest News
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year
Motley Fool âĸ 2026-06-18T13:20:00Z
CRISPR Therapeutics AG (CRSP) Ascends While Market Falls: Some Facts to Note
Zacks âĸ 2026-06-17T21:50:03Z
The Best Biotech Stocks to Buy in 2026
Motley Fool âĸ 2026-06-17T20:20:00Z
Moderna (MRNA) Surges 6.3%: Is This an Indication of Further Gains?
Zacks âĸ 2026-06-17T13:11:00Z
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks âĸ 2026-06-16T13:00:02Z
CRISPR Therapeutics Expands Funding Capacity As Gene Editing Pipeline Advances
Simply Wall St. âĸ 2026-06-13T07:18:55Z
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
Zacks âĸ 2026-06-11T21:50:02Z
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
Zacks âĸ 2026-06-10T22:00:04Z
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
Motley Fool âĸ 2026-06-08T17:13:00Z
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
Insider Monkey âĸ 2026-06-06T00:17:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $213,480,000 | $120,667,000 | $130,250,000 | $110,250,000 |
| Cost Of Revenue | $213,480,000 | $120,667,000 | $130,250,000 | $110,250,000 |
| Total Revenue | $0 | $35,000,000 | $370,000,000 | $436,000 |
| Operating Revenue | $0 | $35,000,000 | $370,000,000 | $436,000 |
| Expenses | ||||
| Total Expenses | $664,571,000 | $501,566,000 | $592,538,000 | $673,597,000 |
| Other Income Expense | $86,606,000 | $103,901,000 | $71,816,000 | $22,661,000 |
| Other Non Operating Income Expenses | $86,606,000 | $103,901,000 | $71,816,000 | $22,661,000 |
| Operating Expense | $451,091,000 | $380,899,000 | $462,288,000 | $563,347,000 |
| Other Operating Expenses | $-3,510,000 | $-2,314,000 | $-1,206,000 | $-762,000 |
| General And Administrative Expense | $73,542,000 | $72,977,000 | $76,162,000 | $102,464,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-581,599,000 | $-366,252,000 | $-153,610,000 | $-650,175,000 |
| Normalized Income | $-581,599,000 | $-366,252,000 | $-153,610,000 | $-650,175,000 |
| Net Income From Continuing And Discontinued Operation | $-581,599,000 | $-366,252,000 | $-153,610,000 | $-650,175,000 |
| Total Operating Income As Reported | $-664,571,000 | $-466,566,000 | $-222,538,000 | $-673,161,000 |
| Net Income Common Stockholders | $-581,599,000 | $-366,252,000 | $-153,610,000 | $-650,175,000 |
| Net Income | $-581,599,000 | $-366,252,000 | $-153,610,000 | $-650,175,000 |
| Net Income Including Noncontrolling Interests | $-581,599,000 | $-366,252,000 | $-153,610,000 | $-650,175,000 |
| Net Income Continuous Operations | $-581,599,000 | $-366,252,000 | $-153,610,000 | $-650,175,000 |
| Pretax Income | $-577,965,000 | $-362,665,000 | $-150,722,000 | $-650,500,000 |
| Operating Income | $-664,571,000 | $-466,566,000 | $-222,538,000 | $-673,161,000 |
| Gross Profit | $-213,480,000 | $-85,667,000 | $239,750,000 | $-109,814,000 |
| Per Share | ||||
| Diluted EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 |
| Basic EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-645,092,000 | $-447,307,000 | $-202,701,000 | $-648,989,000 |
| Reconciled Depreciation | $19,479,000 | $19,259,000 | $19,837,000 | $24,172,000 |
| EBITDA (Bullshit earnings) | $-645,092,000 | $-447,307,000 | $-202,701,000 | $-648,989,000 |
| EBIT | $-664,571,000 | $-466,566,000 | $-222,538,000 | $-673,161,000 |
| Diluted Average Shares | $89,925,109 | $84,359,126 | $79,220,930 | $77,746,575 |
| Basic Average Shares | $89,925,109 | $84,359,126 | $79,220,930 | $77,746,575 |
| Diluted NI Availto Com Stockholders | $-581,599,000 | $-366,252,000 | $-153,610,000 | $-650,175,000 |
| Tax Provision | $3,634,000 | $3,587,000 | $2,888,000 | $-325,000 |
| Research And Development | $381,059,000 | $310,236,000 | $387,332,000 | $461,645,000 |
| Selling General And Administration | $73,542,000 | $72,977,000 | $76,162,000 | $102,464,000 |
| Other Gand A | $73,542,000 | $72,977,000 | $76,162,000 | $102,464,000 |
Fetched: 2026-06-10
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,921,813,000 | $1,932,080,000 | $1,882,787,000 | $1,875,408,000 |
| Total Assets | $2,265,243,000 | $2,242,034,000 | $2,229,571,000 | $2,243,057,000 |
| Total Non Current Assets | $279,572,000 | $304,902,000 | $321,493,000 | $390,031,000 |
| Other Non Current Assets | $31,997,000 | $27,348,000 | $13,566,000 | $16,275,000 |
| Current Assets | $1,985,671,000 | $1,937,132,000 | $1,908,078,000 | $1,853,026,000 |
| Other Current Assets | $9,843,000 | $8,306,000 | $14,386,000 | $37,708,000 |
| Receivables | $0 | $25,000,000 | $200,000,000 | $0 |
| Accounts Receivable | $0 | $25,000,000 | $200,000,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $1,975,828,000 | $1,903,826,000 | $1,693,692,000 | $1,815,318,000 |
| Cash And Cash Equivalents | $347,559,000 | $298,257,000 | $389,477,000 | $211,885,000 |
| Investmentin Financial Assets | - | $0 | $1,973,000 | $53,130,000 |
| Goodwill And Other Intangible Assets | - | $0 | $16,000 | $71,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $206,746,000 | $223,693,000 | $238,632,000 | $244,021,000 |
| Long Term Debt And Capital Lease Obligation | $188,168,000 | $206,405,000 | $223,007,000 | $228,179,000 |
| Current Debt And Capital Lease Obligation | $18,578,000 | $17,288,000 | $15,625,000 | $15,842,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $343,430,000 | $309,954,000 | $346,768,000 | $367,578,000 |
| Total Non Current Liabilities Net Minority Interest | $194,310,000 | $222,172,000 | $237,977,000 | $246,471,000 |
| Other Non Current Liabilities | $6,142,000 | $3,444,000 | $958,000 | $5,969,000 |
| Non Current Deferred Liabilities | $0 | $12,323,000 | $14,012,000 | $12,323,000 |
| Current Liabilities | $149,120,000 | $87,782,000 | $108,791,000 | $121,107,000 |
| Other Current Liabilities | $13,113,000 | $10,417,000 | $5,141,000 | $20,000 |
| Current Deferred Liabilities | $15,771,000 | $3,845,000 | $4,105,000 | $0 |
| Payables And Accrued Expenses | $101,658,000 | $56,232,000 | $83,920,000 | $105,245,000 |
| Payables | $12,251,000 | $15,160,000 | $38,585,000 | $27,563,000 |
| Total Tax Payable | $1,113,000 | $451,000 | $438,000 | $135,000 |
| Accounts Payable | $11,138,000 | $14,709,000 | $38,147,000 | $27,428,000 |
| Equity | ||||
| Common Stock Equity | $1,921,813,000 | $1,932,080,000 | $1,882,803,000 | $1,875,479,000 |
| Total Equity Gross Minority Interest | $1,921,813,000 | $1,932,080,000 | $1,882,803,000 | $1,875,479,000 |
| Stockholders Equity | $1,921,813,000 | $1,932,080,000 | $1,882,803,000 | $1,875,479,000 |
| Gains Losses Not Affecting Retained Earnings | $4,821,000 | $1,840,000 | $1,913,000 | $-15,647,000 |
| Other Equity Adjustments | $4,821,000 | $1,840,000 | $1,913,000 | $-15,647,000 |
| Retained Earnings | $-1,947,551,000 | $-1,365,952,000 | $-999,700,000 | $-846,090,000 |
| Other | ||||
| Treasury Shares Number | $115,316 | $170,316 | $170,316 | $180,316 |
| Ordinary Shares Number | $95,894,341 | $85,741,981 | $80,044,378 | $78,512,450 |
| Share Issued | $96,009,657 | $85,912,297 | $80,214,694 | $78,692,766 |
| Tangible Book Value | $1,921,813,000 | $1,932,080,000 | $1,882,787,000 | $1,875,408,000 |
| Invested Capital | $1,921,813,000 | $1,932,080,000 | $1,882,803,000 | $1,875,479,000 |
| Working Capital | $1,836,551,000 | $1,849,350,000 | $1,799,287,000 | $1,731,919,000 |
| Capital Lease Obligations | $206,746,000 | $223,693,000 | $238,632,000 | $244,021,000 |
| Total Capitalization | $1,921,813,000 | $1,932,080,000 | $1,882,803,000 | $1,875,479,000 |
| Treasury Stock | $60,000 | $62,000 | $62,000 | $63,000 |
| Additional Paid In Capital | $3,861,516,000 | $3,293,556,000 | $2,878,155,000 | $2,734,838,000 |
| Capital Stock | $3,087,000 | $2,698,000 | $2,497,000 | $2,441,000 |
| Common Stock | $3,087,000 | $2,698,000 | $2,497,000 | $2,441,000 |
| Non Current Deferred Revenue | $0 | $12,323,000 | $14,012,000 | $12,323,000 |
| Long Term Capital Lease Obligation | $188,168,000 | $206,405,000 | $223,007,000 | $228,179,000 |
| Current Deferred Revenue | $15,771,000 | $3,845,000 | $4,105,000 | $0 |
| Current Capital Lease Obligation | $18,578,000 | $17,288,000 | $15,625,000 | $15,842,000 |
| Current Accrued Expenses | $89,407,000 | $41,072,000 | $45,335,000 | $77,682,000 |
| Net PPE | $247,575,000 | $277,554,000 | $305,938,000 | $320,555,000 |
| Accumulated Depreciation | $-91,052,000 | $-72,272,000 | $-53,433,000 | $-33,832,000 |
| Gross PPE | $338,627,000 | $349,826,000 | $359,371,000 | $354,387,000 |
| Leases | $146,667,000 | $145,852,000 | $143,260,000 | $141,680,000 |
| Construction In Progress | $3,955,000 | $6,118,000 | $8,859,000 | $6,162,000 |
| Other Properties | $175,299,000 | $185,469,000 | $195,404,000 | $194,818,000 |
| Machinery Furniture Equipment | $12,706,000 | $12,387,000 | $11,848,000 | $11,727,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $1,628,269,000 | $1,605,569,000 | $1,304,215,000 | $1,603,433,000 |
| Investments And Advances | - | $0 | $1,973,000 | $53,130,000 |
| Available For Sale Securities | - | - | $1,973,000 | $53,130,000 |
Fetched: 2026-06-10
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-370,928,000 | $-144,675,000 | $-272,345,000 | $-532,929,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-345,014,000 | $-142,774,000 | $-260,375,000 | $-495,741,000 |
| Cash Flow From Continuing Operating Activities | $-345,014,000 | $-142,774,000 | $-260,375,000 | $-495,741,000 |
| Investing Activities | ||||
| Capital Expenditure | $-25,914,000 | $-1,901,000 | $-11,970,000 | $-37,188,000 |
| Investing Cash Flow | $-31,805,000 | $-280,481,000 | $374,647,000 | $-258,655,000 |
| Cash Flow From Continuing Investing Activities | $-31,805,000 | $-280,481,000 | $374,647,000 | $-258,655,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $398,090,000 | $300,695,000 | $32,721,000 | $970,000 |
| Financing Cash Flow | $426,026,000 | $331,984,000 | $62,664,000 | $38,592,000 |
| Cash Flow From Continuing Financing Activities | $426,026,000 | $331,984,000 | $62,664,000 | $38,592,000 |
| Net Common Stock Issuance | $398,090,000 | $300,695,000 | $32,721,000 | $970,000 |
| Common Stock Issuance | $398,090,000 | $300,695,000 | $32,721,000 | $970,000 |
| Other | ||||
| End Cash Position | $359,078,000 | $309,776,000 | $401,068,000 | $224,060,000 |
| Beginning Cash Position | $309,776,000 | $401,068,000 | $224,060,000 | $939,944,000 |
| Effect Of Exchange Rate Changes | $95,000 | $-21,000 | $73,000 | $-80,000 |
| Changes In Cash | $49,207,000 | $-91,271,000 | $176,935,000 | $-715,804,000 |
| Proceeds From Stock Option Exercised | $27,936,000 | $31,289,000 | $29,943,000 | $37,622,000 |
| Net Investment Purchase And Sale | $-5,891,000 | $-278,580,000 | $386,617,000 | $-221,467,000 |
| Sale Of Investment | $1,011,979,000 | $1,207,799,000 | $1,452,528,000 | $1,196,333,000 |
| Purchase Of Investment | $-1,017,870,000 | $-1,486,379,000 | $-1,065,911,000 | $-1,417,800,000 |
| Net Intangibles Purchase And Sale | $-25,000,000 | $0 | $-2,500,000 | $0 |
| Purchase Of Intangibles | $-25,000,000 | $0 | $-2,500,000 | $0 |
| Net PPE Purchase And Sale | $-914,000 | $-1,901,000 | $-9,470,000 | $-37,188,000 |
| Purchase Of PPE | $-914,000 | $-1,901,000 | $-9,470,000 | $-37,188,000 |
| Change In Working Capital | $71,882,000 | $156,270,000 | $-193,585,000 | $19,845,000 |
| Change In Other Working Capital | $-5,607,000 | $-6,356,000 | $3,333,000 | $14,299,000 |
| Change In Other Current Liabilities | $4,258,000 | $9,624,000 | $110,000 | $-1,521,000 |
| Change In Payables And Accrued Expense | $44,894,000 | $-27,283,000 | $-20,247,000 | $5,164,000 |
| Change In Prepaid Assets | $3,337,000 | $5,285,000 | $23,219,000 | $1,598,000 |
| Change In Receivables | $25,000,000 | $175,000,000 | $-200,000,000 | $305,000 |
| Changes In Account Receivables | $25,000,000 | $175,000,000 | $-200,000,000 | $305,000 |
| Other Non Cash Items | $72,725,000 | $-38,618,000 | $-14,045,000 | $12,470,000 |
| Stock Based Compensation | $72,499,000 | $86,567,000 | $81,028,000 | $97,947,000 |
| Depreciation Amortization Depletion | $19,479,000 | $19,259,000 | $19,837,000 | $24,172,000 |
| Depreciation And Amortization | $19,479,000 | $19,259,000 | $19,837,000 | $24,172,000 |
| Depreciation | $19,400,000 | $19,200,000 | - | - |
| Net Income From Continuing Operations | $-581,599,000 | $-366,252,000 | $-153,610,000 | $-650,175,000 |
| Amortization Of Securities | - | - | - | - |
| Earnings Losses From Equity Investments | - | - | - | - |
| Gain Loss On Sale Of Business | - | - | - | - |
Fetched: 2026-06-10